



**WORLD  
CORNEA VIII  
CONGRESS**

**WORLD CORNEA CONGRESS VIII  
SUBMISSION GUIDE**

WORLD CORNEA CONGRESS VIII SUBMISSIONS: AUGUST 26 – OCTOBER 20, 2019



# WORLD CORNEA VIII CONGRESS

---

## IMPORTANT DATES

---

August 26	<ul style="list-style-type: none"><li>○ Abstract submissions for WCC scientific papers and electronic posters opens</li><li>○ 2020 Financial Interest Disclosure and ASCRS Faculty CME Review opens</li></ul>
October 20	<ul style="list-style-type: none"><li>○ Deadline for abstract submissions for WCC scientific papers and electronic posters</li><li>○ Deadline to complete 2020 Financial Interest Disclosure and ASCRS Faculty CME Review</li></ul>
December 23	WCC acceptances sent via email
December 30 – April 27	Electronic posters can be uploaded
February 3	WCC Program available online
April 27	Deadline to upload all electronic posters
May 14-15	World Cornea Congress



---

## FACULTY GUIDELINES

---

Abstract submissions for the World Cornea Congress Program must take place through the online submission portal at <https://wcc.confex.com/wcc/20cw/cfp.cgi>

All abstract submissions are subject to the ACCME guidelines regarding independence and validation of clinical content. Instructors and authors are responsible for ensuring that (1) all recommendations involving clinical medicine presented are based on evidence that is accepted within the profession and (2) all scientific research referred to, reported, or used conforms to the generally accepted standards of experimental design, data collection, and analysis. Recommendations, treatments, or manners of practicing medicine that do not comply with the above, are known to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients will not be accepted.

General statements about abstract submissions are followed by requirements for either scientific papers or electronic posters on the following pages.

### ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Society of Cataract and Refractive Surgery (ASCRS) and the Cornea Society. The ASCRS is accredited by the ACCME to provide continuing medical education for physicians.

### EDUCATIONAL OBJECTIVES

Ophthalmologists attending the World Cornea Congress VIII will be able to:

- Improve diagnostic skills, discuss treatment options, and integrate updated protocols related to ocular infections
- Describe current research on the risk factors for, diagnosis of, and treatment options for keratoconus and other ectatic disorders
- Evaluate current and emerging options in penetrating keratoplasty and keratoprotheses
- Compare and contrast lamellar and endothelial keratoplasty techniques, and implement surgical technique modifications as necessary to improve outcomes
- Evaluate and describe intraocular and corneal-based refractive surgery treatment options
- Explain current research related to the etiology and treatment of ocular surface diseases
- Describe current issues affecting global eye health and eye banking



## ABSTRACT SUBMISSION PROCESS

Online abstract submission is open from August 26 to October 20, 2019.

**Step 1:** Go to <https://ascrs.confex.com/ascrs/20am/cfp.cgi> to submit an abstract for a WCC scientific paper or electronic poster:

- Provide all required information. The process will allow you to review your submission.
- It is important to use a valid e-mail address as all correspondence regarding the account and/or submission will be sent to this e-mail address.

**Step 2:** Complete the Financial Interest Disclosure and ASCRS Faculty CME Review at <https://ascrs.confex.com/ascrs/ficme20/cfp.cgi>

All faculty in a position to control the content of this CME activity—presenters, instructors, co-instructors, authors, and other faculty—must complete the ASCRS Faculty CME Review and Financial Interest Disclosure. Instructions on how to complete the ASCRS Faculty CME Review and Financial Interest Disclosure on page 5. **Failure to complete by Sunday, October 20 will result in disqualification from participation in this CME activity.** It's only necessary to submit one Financial Interest Disclosure for 2020. Once you submit a disclosure, it will be applied to all activities until August 2020.

**Step 3:** Use your browser "print" command to print or save a copy of your submission for your records. If you do not receive a completed submission confirmation ID, please contact: [cbraden@ascrs.org](mailto:cbraden@ascrs.org). Incomplete abstract submissions will not be processed.

Faculty can repeat Step 1 to submit multiple abstracts.

## PEER REVIEW PROCESS

All abstract submissions will be peer-reviewed by the WCC Program Committee. Abstract submissions will be evaluated on content and scientific integrity and will be accepted based on WCC creating an overall balanced program. Submissions by non-MDs/DOs will be reviewed in the context of the presenter's training and education, as well as how the topic fits into the overall program. Abstract submissions should align with WCC educational objectives.

## DISCLOSURE OF UNAPPROVED/OFF-LABEL USE

If a presentation concerns the use of a drug or device that has not been approved by the U.S. Food and Drug Administration or concerns off-label use of a drug or device approved by the FDA for other use, this must be disclosed during the presentation.

## NOTIFICATION OF ABSTRACT ACCEPTANCE/NON-ACCEPTANCE

An e-mail with the status of the abstract submission will be sent by December 23 to the email listed for the primary author. If notification is not received by December 30, please contact: [cbraden@ascrs.org](mailto:cbraden@ascrs.org).

## REASONS FOR NON-ACCEPTANCE

The World Cornea Congress Program Committee will not accept abstracts under the following circumstances:

- Abstract submissions that are commercially biased



- Abstract submissions from owners and/or employees of ACCME-defined commercial interests
- If the lead author and co-authors have not completed their individual ASCRS Faculty CME Review and Financial Interest Disclosure by the submission deadline
- If the submission's content/research has been published or presented elsewhere. Abstracts submitted to both World Cornea Congress VIII and the ASCRS Annual Meeting 2020 will only be accepted for one meeting.

### **SUBMISSION WITHDRAWALS**

If an instructor/author/producer is unable to present, he/she must notify the Cornea Society by e-mail, [cbraden@ascrs.org](mailto:cbraden@ascrs.org).

---

### **COPYRIGHT ASSIGNMENT STATEMENTS**

---

By submitting this abstract (paper or electronic poster), I agree to grant and assign exclusively to the Cornea Society ("the society") all of the rights, including copyright, in the submitted presentation, as well as any related materials used for audiovisual presentation (collectively referred to as "the works"). I also grant and assign to the society the rights to film, record, reproduce, reprint, distribute, sell, and otherwise make use of the works, or any presentation of the works, in any media or format, and authorize the society to use my name, likeness, photograph, and biographical data in connection with its use and promotion of the works. I understand that I will receive no royalty or other monetary compensation from the society for this assignment of rights and the subsequent use of my works by the society.

I represent and warrant that the works are my own original work or that I have obtained all necessary permissions and authorizations from all individuals or entities that may otherwise have a right, title, or interest in the works; that I have full right and power to make this assignment; that the works do not violate any copyright, proprietary or personal rights of others; and that the works are factually accurate and contain no matter libelous or otherwise unlawful.

---

### **FINANCIAL INTEREST DISCLOSURE AND ASCRS FACULTY CME REVIEW**

---

#### **FINANCIAL INTEREST DISCLOSURE REQUIREMENTS**

ASCRS is the CME provider for World Cornea Congress VIII. As an accredited provider by the ACCME, ASCRS must ensure balance, independence, objectivity, and scientific rigor in all its individually or jointly provided activities.

All individuals participating in an ASCRS CME activity must disclose any financial interest or relationship with a company that produces, markets, resells, or distributes ophthalmic products/devices/drugs or services discussed in an educational presentation or lack thereof. Financial interest can include such things as grants or research support, consultant, stockholder, member of speaker's bureau, financial relationships held by spouse, etc. The intent of the financial interest disclosure is to provide information to the ASCRS Program Committee and ASCRS Clinical Education department to



design and implement a balanced, independent, and scientific educational activity. The Financial Interest Index in the Real Time Program and Meeting App provides information to attendees, so they can make their own judgment regarding the interest or relationship and the materials presented.

Potential faculty in ASCRS-sponsored and jointly provided CME activities, including instructors, authors, producers, co-instructors, coauthors, presenters, panelists etc., must provide a complete listing of ALL financial relationships relevant to ophthalmology—not just those related to a specific talk—in the financial interest disclosure database. Any relevant financial relationship that occurred within the previous 12 months must be reported. Those who have no financial interests to disclose should indicate “none” in the database. Disclosure information will be kept on file and used during the calendar year in which it was collected for all CME-bearing activities.

To submit an abstract for the World Cornea Congress VIII, you must complete the Financial Interest Disclosure and ASCRS Faculty CME Review in the database. All lead faculty must notify all co-authors that they must enter their financial interest disclosure information. Abstract submissions with incomplete Financial Interest Disclosures and/or ASCRS Faculty CME Review will not be accepted for presentation.

#### **ASCRS FACULTY CME REVIEW**

The ASCRS Faculty CME Review has been developed to provide faculty with information concerning crucial ASCRS CME policies and procedures. Adherence to these policies and procedures ensures balance, independence, objectivity, and scientific rigor in all its activities.

The faculty members who participate in the World Cornea Congress VIII who must complete the ASCRS Faculty CME Review, include:

- Planners, presenters, moderators and panelists for General Sessions and Symposia
- Lead authors/presenters of scientific papers
- Lead authors of scientific posters

#### **COMPLETING FINANCIAL INTEREST DISCLOSURE AND ASCRS FACULTY CME REVIEW**

Go to <https://ascrs.confex.com/ascrs/ficme20/cfp.cgi> and click on “Submit Financial Interest Disclosure and ASCRS Faculty CME Review”

All Faculty will need to verify their personal information and complete their Financial Interest Disclosure and ASCRS Faculty CME Review.

In addition to the written financial interest disclosure, all presenters must disclose financial relationships (or lack thereof) at the start of live presentations.

The Financial Interest Disclosures and ASCRS Faculty CME Review ensure ASCRS’ continued compliance with the ACCME’s guidelines and ensures the society provides exceptional quality continuing education.



---

## PARTICIPATION OF OWNERS/EMPLOYEES OF ACCME-DEFINED COMMERCIAL INTERESTS IN CME ACTIVITIES

---

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), ASCRS must ensure balance, independence, objectivity, and scientific rigor in all its individually or jointly provided CME activities.

**For the World Cornea Congress, the WCC Program Committee will not accept abstracts for electronic posters or scientific papers that are submitted by owners and/or employees of ACCME-defined commercial interests except under the circumstances listed below.** For WCC general sessions and/or symposia, permission to invite an owner/commercial employee to participate as faculty must be obtained in advance from the WCC Program Committee and the owner/employee's participation must be closely monitored by the session planner.

Commercial interest employees shall not participate in the planning of any ASCRS CME activities or ASCRS jointly provided activities. Owners/Employees of an ACCME defined commercial interest may serve as instructors or faculty in ASCRS CME activities or jointly provided activities under the following limited circumstances:

1. When the topic and content are non-clinical in nature; i.e. ASCRS operational announcements such as, ASCRS Foundation and Government Relations updates, leadership, practice management and business topics and/or the topic and content is not related to the business lines or products of the presenter's employer.
2. When the content is related to the scientific or discovery process itself, the result of basic research studies relevant to the clinical problem being addressed but not specific to a commercial product or its preclinical and clinical testing and/or recommendations regarding patient care.
3. When commercial interest owners and/or employees are participating as technicians teaching the safe and proper use of medical devices during hands-on skills transfer sessions. In this circumstance, content must not be related to clinical recommendations concerning the business lines or products of their employer. Commercial interest owners and/or employees who provide technical assistance are required to follow ASCRS's policies and guidelines regarding participation during skills transfer sessions. It is the responsibility of ASCRS staff or the designated session leader to appropriately monitor the owner/employee participation to ensure adherence to ASCRS policies and guidelines.

Owners/Employees of commercial interests are required to submit their Financial Interest Disclosure so any potential conflicts can be resolved prior to the presentation and proper disclosure can be made to learners. All presentations submitted for consideration under the narrowly defined circumstances listed above will be reviewed by the ASCRS Program Committee and/or ASCRS Education Committee to ensure compliance.

The ACCME defines a commercial interest as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

The following organizations are not considered commercial interest by ACCME:

- 501-C Non-profit organizations (except when the organization advocates for commercial interests)
- Government organizations



- Non-health care related companies
- Liability insurance providers
- Health insurance providers
- Group medical practices
- For-profit hospitals
- For profit rehabilitation centers
- For-profit nursing homes
- Blood banks
- Diagnostic laboratories (if its business is limited to the provision of diagnostic services that provide clinical results or information to healthcare professionals for their treatment of patients.)
- Providers of clinical service directly to patients unless the provider is owned, or controlled by, a commercial interest.

---

## PAPERS AND ELECTRONIC POSTER CATEGORIES AND TOPICS

---

### **CATARACT SURGERY IN THE CORNEAL PATIENT**

### **CLINICAL TRIALS IN CORNEA**

### **CONTACT LENSES IN THE MANAGEMENT OF CORNEAL DISEASE**

### **CORNEAL ANATOMY**

### **CORNEAL ANGIOGENESIS**

### **CORNEAL BIOLOGY**

### **CORNEAL DISEASE IN CHILDREN**

### **CORNEAL DYSTROPHIES**

Fuchs dystrophy

Other endothelial dystrophies

Stromal Dystrophies

Epithelial and Basement Membrane Dystrophies

### **CORNEAL IMAGING**

### **CORNEAL INFECTIONS**

Bacterial keratitis

Parasitic Keratitis (including Acanthamoeba and other parasites)

Fungal Keratitis





Viral Keratitis (including Herpes Simplex, Herpes Zoster and other Viral)  
Other infections

**CORNEAL SURGERY**

EK  
DMEK  
DSAEK  
DALK  
PK  
Descemet stripping (DSO/DWEK)  
Keratoprosthesis  
Ocular Surface Reconstruction

**CORNEAL TRAUMA (including burns)**

**EYE BANKING**

**ENDOTHELIAL REGENERATION (including cell therapy and medications)**

**GENETICS OF CORNEAL DISEASE**

**IMMUNOLOGICAL DISORDERS**

Stevens-Johnson Syndrome  
Mucous Membrane Pemphigoid  
Graft versus Host Disease  
Peripheral Ulcerative Keratitis  
Corneal Graft Rejection

**KERATOCONUS AND OTHER ECTATIC DISORDERS**

Epidemiology  
Diagnosis  
Management  
Disease Progression  
Contact Lenses  
Crosslinking  
Intrastromal Ring Segments

**MISCELLANEOUS (TOPIC NOT COVERED ELSEWHERE)**

**OCULAR SURFACE**

Dry Eye Disease  
Sjögren's Syndrome  
Dry Eye Treatments  
Tear Film Measurement Devices



Meibomian Gland Dysfunction  
Ocular Surface Tumors  
Pterygium/Pinguecula  
Neurotrophic Keratitis  
Limbal Stem Cell Dysfunction  
Allergic Eye Diseases

#### **REFRACTIVE SURGERY**

#### **SYSTEMIC DISEASES AND THE CORNEA**

Aniridia  
Corneal Complications from Systemic Medications

---

### **WCC SCIENTIFIC PAPER SUBMISSION: INSTRUCTIONS AND CHECKLIST**

---

SUBMISSION DEADLINE: OCTOBER 20, 2019

Because of repetition and time limitations, abstract submissions are limited to 3 abstracts per author. Please submit in order of your preference of acceptance.

#### **SCIENTIFIC PAPER PRESENTATIONS**

All accepted scientific papers will be limited to 5-minute presentations. Within each session, papers will be clustered into discussion groups, typically 3 to 5 related papers. After each cluster, there will be a panel discussion.

#### **PEER REVIEW**

All scientific paper abstract submissions will be peer-reviewed by the WCC Program Committee. Abstracts will be graded on content and scientific integrity. Submissions by non-MDs/DOs will be reviewed in the context of the presenter's training and education.

#### **RESPONSIBILITIES OF THE LEAD AUTHOR**

- Prior to submitting, the lead author must complete their Financial Interest Disclosure and ASCRS Faculty CME Review.
- Lead authors must notify coauthors to enter their Financial Interest Disclosure by October 20, 2019. Authors who do not complete the process cannot be included on the abstract.

#### **ABSTRACT STRUCTURE**

Please read the following instructions carefully before completing the submission:



**Title** (limited to 140 characters, including spaces and punctuation)

For CME purposes, product/trade names cannot be used in the title. Generic descriptors are required. Titles with product/trade names may be rejected. The title should not be formulated as a question or statement (i.e., should not include a verb). Titles should follow title case rules and may be edited by ASCRS editorial staff. Please use title case when completing the submission. The title should accurately and concisely reflect the submission content.

**Category** Choose from the categories and topics on page 6.

**Purpose** (Limited to 350 characters, including spaces and punctuation)

Indicate the question that the study answers or the hypothesis it tests. Do not include names or affiliations of authors. Do not include sponsorships, grants, etc.

**Methods** (Limited to 700 characters, including spaces and punctuation)

Describe the study design, indicating randomization, masking, and whether the data collection was retrospective or prospective, if applicable. Identify the patients, including selection procedures, inclusion criteria, and numbers. Indicate the intervention procedures and the outcome measures.

**Results** (Limited to 700 characters, including spaces and punctuation)

Present the outcomes and measurements. Data should include the level of statistical significance.

**Conclusion** (Limited to 350 characters including spaces and punctuation)

State the conclusion and clinical pertinence.

- Abstracts that do not include results and conclusion **must be revised by March 3, 2020**, to be accepted in the ASCRS Program. This date applies to papers and posters only.
- Proofread the abstract carefully. It will appear exactly as submitted.
- Do not submit the abstract if the material has been presented or published elsewhere.

Please ensure you have listed all contributing authors on the abstract and that the contributing authors have completed their Financial Interest Disclosure by the October 20, 2019 deadline. Coauthors who are not listed on the abstract submission and/or have not completed a Financial Interest Disclosure cannot be acknowledged within the presentation. There is a limit of 6 authors per submission.

**WCC SCIENTIFIC PAPER SUBMISSION CHECKLIST**

- ✓ Lead author must complete Financial Interest Disclosure and ASCRS Faculty CME Review before submitting.
- ✓ Notify all coauthors that they must complete their Financial Interest Disclosure by the October 20 deadline.
- ✓ Confirm the valid e-mail address of each coauthor before starting the online submission process.
- ✓ Confirm that title does not include product/trade names and is in the proper format.
- ✓ Confirm that abstract includes 4 required sections: purpose, methods, results, conclusion.
- ✓ Ensure that each section of the abstract adheres to the character limit.



---

## WCC ELECTRONIC POSTER SUBMISSION: INSTRUCTIONS AND CHECKLIST

---

**SUBMISSION DEADLINE: OCTOBER 20, 2019**  
**ALL ELECTRONIC POSTER DUE: APRIL 27, 2020**

Limit: 3 poster abstract submissions per author

### **ELECTRONIC POSTER PRESENTATIONS**

All accepted and uploaded electronic posters will be available for viewing on-demand in the World Cornea Congress Poster Pavilion at the convention center during the meeting. Questions from attendees will be submitted electronically to the lead author's email.

### **PEER REVIEW**

All poster abstract submissions will be peer reviewed by the WCC Program Committee. Abstracts will be graded on content and scientific integrity. Submissions by non-MDs/DOs will be reviewed in the context of the presenter's training and education.

### **RESPONSIBILITIES OF THE LEAD AUTHOR**

- Prior to submitting, the lead author must complete their Financial Interest Disclosure and ASCRS Faculty CME Review.
- Lead authors must notify coauthors to submit their Financial Interest Disclosure. Those who have not submitted by October 20 cannot be included on the abstract.
- In submitting a poster, the lead author attests that he/she has reviewed each coauthor's financial interests and determined there is no conflict of interest.

### **STRUCTURED ABSTRACT**

Please read the following instructions carefully before completing the submission:

- Choose the poster category from the list on page 6.
- Do not use all capital letters when completing the submission.
- The title should accurately and concisely reflect the submission content.

For CME purposes, product/trade names cannot be used in the title. Generic descriptors are required. Titles with product/trade names may be rejected. The title should not be formulated as a question or statement (i.e., should not include a verb). Titles should follow title case rules and may be edited by ASCRS editorial staff.

Limit: 140 characters including spaces and punctuation

Limit: 6 contributing authors



**NOTE:** Coauthors who have not been indicated on the abstract submission and/or have not completed their Financial Interest Disclosure cannot be acknowledged on electronic poster presentation and will be removed prior to the ASCRS Annual Meeting. Please ensure you have listed all contributing authors on the abstract and that the contributing authors have submitted current financial interest disclosures in the submission database before the October 20 deadline.

**Purpose** (Limited to 350 characters, including spaces and punctuation)

Indicate the question that the study answers or the hypothesis it tests. Do not include names or affiliations of authors. Do not include sponsorships, grants, etc.

**Methods** (Limited to 700 characters, including spaces and punctuation)

Describe the study design, indicating randomization, masking, and whether the data collection was retrospective or prospective, if applicable. Identify the patients, including selection procedures, inclusion criteria, and numbers. Indicate the intervention procedures and the outcome measures.

**Results** (Limited to 700 characters, including space and punctuation)

Present the outcomes and measurements. Data should include the level of statistical significance.

**Conclusion** (Limited to 350 characters, including space and punctuation)

State the conclusion and clinical pertinence.

- Abstracts that do not include final results and conclusion must be revised by March 2, 2020 to be included with the online abstracts. This date applies to papers and posters only.
- Proofread the abstract carefully. It will appear exactly as submitted.
- Do not submit the abstract if the material has been presented or published elsewhere.

#### **ELECTRONIC FORMAT FOR ACCEPTED POSTERS**

- Electronic Posters must be uploaded as PowerPoint Files (.PPT or .PPTX, only). Maximum of 12 PowerPoint Slides (file size of 50 MB)
- Any combination of PowerPoint slides with images, tables, and text accepted.
- Videos and/or animation cannot be embedded in the PowerPoint file.
- An additional file upload containing supporting multimedia file is available (Limit: 1 file; 50 MB max)
- PowerPoint file should not be password protected.
- Do not submit the poster as a single slide.
- Title slide must include financial interest statement, or lack thereof, for all authors listed on the abstract.



#### **WCC ELECTRONIC POSTER SUBMISSION CHECKLIST**

- ✓ Lead author must complete their Financial Interest Disclosure and ASCRS Faculty CME Review before submitting.
- ✓ Notify all coauthors that they must complete their Financial Interest Disclosure by the October 20 deadline.
- ✓ Confirm the valid e-mail address of each coauthor before starting the online submission process.
- ✓ Check that title does not include product/trade names and is in the proper format.
- ✓ Confirm that abstract includes 4 required sections: purpose, methods, results, conclusion.